Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments [ID4026]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 9 August 2024Expected publication date: TBC
Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (Review of TA869) [ID6333]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 13 August 2024Expected publication date: TBC